C. Le Pen

891 total citations
30 papers, 689 citations indexed

About

C. Le Pen is a scholar working on Economics and Econometrics, Ophthalmology and General Health Professions. According to data from OpenAlex, C. Le Pen has authored 30 papers receiving a total of 689 indexed citations (citations by other indexed papers that have themselves been cited), including 10 papers in Economics and Econometrics, 5 papers in Ophthalmology and 4 papers in General Health Professions. Recurrent topics in C. Le Pen's work include Health Systems, Economic Evaluations, Quality of Life (8 papers), Pharmaceutical Economics and Policy (7 papers) and Glaucoma and retinal disorders (4 papers). C. Le Pen is often cited by papers focused on Health Systems, Economic Evaluations, Quality of Life (8 papers), Pharmaceutical Economics and Policy (7 papers) and Glaucoma and retinal disorders (4 papers). C. Le Pen collaborates with scholars based in France, Japan and Italy. C. Le Pen's co-authors include Émile Lévy, A Basdevant, Pierre Lévy, Friedemann Loos, J. N. Beuzen, J.–F. Rouland, Christophe Baudouin, Isabelle Bardoulat, Nicolás Meyer and Ortonne Jp and has published in prestigious journals such as Journal of Affective Disorders, Journal of Epidemiology & Community Health and Investigative Ophthalmology & Visual Science.

In The Last Decade

C. Le Pen

27 papers receiving 638 citations

Peers

Countries citing papers authored by C. Le Pen

Since Specialization

Citations

This map shows the geographic impact of C. Le Pen's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by C. Le Pen with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites C. Le Pen more than expected).

Fields of papers citing papers by C. Le Pen

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by C. Le Pen. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by C. Le Pen. The network helps show where C. Le Pen may publish in the future.

Co-authorship network of co-authors of C. Le Pen

This figure shows the co-authorship network connecting the top 25 collaborators of C. Le Pen. A scholar is included among the top collaborators of C. Le Pen based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with C. Le Pen. C. Le Pen is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Télémédecine et dépenses de santé – une modélisation économique évaluant l’impact d’une intervention en télémédecine dans trois pathologies chroniques : diabète de type 2, hypertension artérielle et cancer de la prostate 2018 ·Revue d Épidémiologie et de Santé Publique ·(unknown), C. Le Pen, Isabelle Bardoulat, (unknown), (unknown), Manon Belhassen, F. Depont, Éric Van Ganse	1
2	To What Extent Can Biosimilars Compete with Brand Name Biologics? A EU-5 Granulocyte-Colony Stimulating Factors Markets Analysis 2013 ·Value in Health ·(unknown), Pascal Paubel, (unknown), (unknown), C. Le Pen, (unknown)	1
3	Hospital Reimbursement Price Cap for Cancer Drugs 2012 ·PharmacoEconomics ·(unknown), (unknown), (unknown), (unknown), C. Le Pen, Pascal Paubel	9
4	PHP9 Temporary Use Authorizations: The Economic and Clinical Future of Drugs Used in the French Compassionate Program 2011 ·Value in Health ·(unknown), Pascal Paubel, (unknown), C. Le Pen, (unknown)	0
5	Psoriasis: an epidemiological evaluation of disease burden in 590 patients 2010 ·Journal of the European Academy of Dermatology and Venereology ·Nicolás Meyer, C. Paul, (unknown), Isabelle Bardoulat, (unknown), (unknown), (unknown), C. Le Pen, Ortonne Jp	90
6	PHP30 PRIMARY CARE AND AVOIDABLE HOSPITALIZATIONS: A COMPARATIVE ANALYSIS BETWEEN FRANCE AND THE UK 2009 ·Value in Health ·Essam Mansour, C. Le Pen, (unknown), (unknown)	0
7	Treatment Carryover Impacts on Effectiveness of Intraocular Pressure Lowering Agents, Estimated by a Discrete Event Simulation Model 2008 ·European Journal of Ophthalmology ·Philippe Denis, C. Le Pen, (unknown), G Berdeaux	6
8	Cost‐minimization study comparing Simulect^® vs. Thymoglobulin^® in renal transplant induction 2004 ·Clinical Transplantation ·(unknown), (unknown), C. Le Pen, M. Büchler, (unknown), (unknown), O Reigneau, Yvon Lebranchu	23
9	The burden cost of French patients suffering from irritable bowel syndrome 2004 ·Scandinavian Journal of Gastroenterology ·C. Le Pen, (unknown), (unknown), M Amouretti, Gilles Bommelaer, Jacques Frexinos, Thierry Poynard, Frédérique Maurel, (unknown), (unknown)	23
10	Naturalistic, Prospective Study of Glaucoma and Ocular Hypertension Treatment in France: Strategies, Clinical Outcomes, and Costs at 1 Year 2003 ·Investigative Ophthalmology & Visual Science ·E Sellem, (unknown), Erwan Piriou, C. Le Pen	5
11	What criteria for pharmaceuticals reimbursement? 2003 ·The European Journal of Health Economics ·C. Le Pen, (unknown), (unknown)	28
12	Naturalistic, Prospective Study of Glaucoma and Ocular Hypertension Treatment in France: Strategies, Clinical Outcomes, and Costs at 1 Year 2003 ·European Journal of Ophthalmology ·(unknown), C. Le Pen, (unknown)	36
13	The epidemiology, economics and quality of life burden of age-related macular degeneration in France, Germany, Italy and the United Kingdom 2002 ·The European Journal of Health Economics ·Julia Bonastre, C. Le Pen, (unknown), Ariel B. Ganz, Patrizia Berto, G Berdeaux	44
14	Cost-minimization study comparing simulect versus thymoglobulin in renal transplant induction 2001 ·Transplantation Proceedings ·(unknown), C. Brun, C. Le Pen, M. Büchler, (unknown), O Reigneau, Yvon Lebranchu	8
15	A comparison of radiopharmaceutical agents used for the diagnosis of pulmonary embolism 2001 ·Nuclear Medicine Communications ·N. Rizzo, Alessandra Farina, C. Le Pen, M. Duet, O. Mundler, R. Leverge	2
16	The Long-Term Effectiveness of Preventive Strategies for Osteoporosis in Postmenopausal Women: A Modeling Approach 2000 ·Osteoporosis International ·C. Le Pen, Françoise Maurel, Gérard Bréart, Patrice Lopès, P.-F. Plouin, (unknown), Christian Roux	11
17	Erythropoietin and preoperative autologous blood donation in the prevention of hepatitis C infection:necessity or luxury? 1999 ·Transfusion ·M.‐C. Woronoff‐Lemsi, (unknown), Samuel Limat, Pascal Morel, C. Le Pen, Jean‐Yves Cahn	11
18	Drug Pricing and Reimbursement in France 1996 ·PharmacoEconomics ·C. Le Pen	9
19	The cost of treatment dropout in depression A cost-benefit analysis of fluoxetine vs. tricyclics 1994 ·Journal of Affective Disorders ·C. Le Pen, Émile Lévy, (unknown), J. N. Beuzen, (unknown)	71
20	[The socio-economics of venous diseases: the findings of a survey of consumers of vasotonic medications in France]. 1993 ·PubMed ·C. Le Pen, E Lévy	3

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact